$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
奥希替尼(Osimertinib)的用法用量:用药指南,剂量调整,特殊人群用药,用药注意事项
2025-10-19 11:44:20
Check Details
FDA批准奥希替尼(Osimertinib)作为EGFR突变非小细胞肺癌的一线治疗药物
2025-10-19 11:44:20
Check Details
FDA批准奥希替尼(Osimertinib)用于治疗EGFRT790M突变阳性非小细胞肺癌
2025-10-19 11:44:20
Check Details
西米普利单抗(Cemiplimab)的副作用如何缓解
2025-10-19 11:44:20
Check Details
西米普利单抗(Cemiplimab)是治疗什么疾病的
2025-10-19 11:44:20
Check Details
西米普利单抗(Cemiplimab)的注意事项和药物相互作用
2025-10-19 11:44:20
Check Details
宗格替尼(Zongertinib)的功效与作用
2025-10-19 11:44:20
Check Details
宗格替尼(Zongertinib)的用药注意事项
2025-10-19 11:44:20
Check Details
康奈非尼(Encorafenib)的副作用有哪些?
2025-10-19 11:44:20
Check Details
宗格替尼(Zongertinib)的副作用如何缓解
2025-10-19 11:44:20
Check Details
西米普利单抗(Cemiplimab)应该如何使用
2025-10-19 11:44:20
Check Details
西米普利单抗(Cemiplimab)会引起哪些副作用
2025-10-19 11:44:20
Check Details
1
2
...
9033
9034
9035
9036
9037
9038
9039
...
10234
10235
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Binimetinib plus Encorafenib for BRAF‑Mutant Melanoma
2
Lemborexant for Insomnia: Dual Orexin 5/10mg, 7-Hour Bedtime, 7–10-Day Review and Safety
3
Fayuvi (rebisufligene etisparvovec-hopf) for MPS IIIA: AAV9 Single Infusion, Weight-Based Dose, Steroids, Liver/Platelet Monitoring
4
Trelagliptin Once-Weekly DPP-4 for Type 2 Diabetes: Dosing, Renal Adjustment, Discontinuation
5
Orforglipron (Foundayo) vs Metformin: Oral GLP-1 Weight Loss and T2D Use
6
Fayuvi (rebisufligene etisparvovec-hopf/UX111) for MPS IIIA: AAV9 SGSH Gene Therapy, Cognition, and Safety
7
Ramosetron Hydrochloride Orally Disintegrating Tablets: A 5-HT3 Receptor Antagonist for Diarrhea-Predominant IBS
8
Finerenone (Kerendia) for Diabetic CKD and HF with LVEF≥40%: Albuminuria, Dosing, Hyperkalemia
9
Baxdrostat (Baxfendy) for Hypertension: Aldosterone Synthase Inhibition, Dosing, and Discontinuation Rules
10
Pixclara (Floretyrosine F-18/18F-FET) Glioma PET: Distinguishing Recurrence from Treatment-Related Change
11
Adagrasib (Krazati) for KRAS G12C: NSCLC Dosing, Titration, and CRC Regulatory Update
12
Bexlutry (Lu-177 Dotatate) for SSTR-Positive GEP-NETs: PRRT Dosing and Safety Monitoring